Age

18–80

Sex

ALL

Healthy volunteers

Not accepted

Participant with 21\<BMI\<40
French participant
Participant able to consent
Participant with social insurance
Participant on peritoneal dialysis for at least 3 months with end-stage renal disease treated

Participant with hypersensibility reactions to apixaban
Participant with a history of major bleeding
Participant already on anticoagulant
Participant on non-stearoid anti-inflammatory at anti-inflammatory dosage \> 300 mg
Participant on potent inhibitors of CYP 3A4 and P-gp
Participant on inducers of CYP3A4 and P-sp
Participant with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
Participant receiving or having received antibiotic treatment within 14 days prior to study
Pregnant or lactating women
Participant with known hypersensitivity reactions to icodextrin
Participant not supporting an intraperitoneal volume of 2 liters (only participant with peritoneal dialysis)
Participant with "Normal renal function" with glomerular filtration rate \< 90 ml/min

Apixaban in Subjects With Peritoneal Dialysis